- Home
- HUYA vs PVLA Comparison
HUYA vs PVLA Comparison
Compare HUYA & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUYA
- PVLA
- Stock Information
- Founded
- HUYA 2014
- PVLA 2015
- Country
- HUYA China
- PVLA United States
- Employees
- HUYA N/A
- PVLA N/A
- Industry
- HUYA Computer Software: Programming Data Processing
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- HUYA Technology
- PVLA Health Care
- Exchange
- HUYA Nasdaq
- PVLA Nasdaq
- Market Cap
- HUYA 713.8M
- PVLA 604.2M
- IPO Year
- HUYA 2018
- PVLA N/A
- Fundamental
- Price
- HUYA $3.04
- PVLA $73.13
- Analyst Decision
- HUYA Buy
- PVLA Strong Buy
- Analyst Count
- HUYA 2
- PVLA 12
- Target Price
- HUYA $4.50
- PVLA $68.67
- AVG Volume (30 Days)
- HUYA 920.8K
- PVLA 199.5K
- Earning Date
- HUYA 11-12-2025
- PVLA 11-15-2025
- Dividend Yield
- HUYA 81.64%
- PVLA N/A
- EPS Growth
- HUYA N/A
- PVLA N/A
- EPS
- HUYA N/A
- PVLA N/A
- Revenue
- HUYA $852,782,043.00
- PVLA N/A
- Revenue This Year
- HUYA $8.16
- PVLA N/A
- Revenue Next Year
- HUYA $5.11
- PVLA N/A
- P/E Ratio
- HUYA N/A
- PVLA N/A
- Revenue Growth
- HUYA N/A
- PVLA N/A
- 52 Week Low
- HUYA $2.21
- PVLA $11.17
- 52 Week High
- HUYA $4.59
- PVLA $77.77
- Technical
- Relative Strength Index (RSI)
- HUYA 41.30
- PVLA 58.85
- Support Level
- HUYA $2.85
- PVLA $70.55
- Resistance Level
- HUYA $3.13
- PVLA $77.77
- Average True Range (ATR)
- HUYA 0.09
- PVLA 4.95
- MACD
- HUYA 0.00
- PVLA -0.60
- Stochastic Oscillator
- HUYA 44.88
- PVLA 64.19
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.